NCT01879241已完成2 期
Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance
University of Ulm15 个研究点 分布在 1 个国家目标入组 252 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 252
- 试验地点
- 15
- 主要终点
- Survival in ALS-Patients with Rasagiline compared to placebo
研究概览
简要总结
The primary objective of the trial is to investigate the survival time (the time from randomization until death or end of the trial) compared between control group and experimental group.
This is a prospective, multicenter, randomized, stratified, parallel-group, double-blind trial comparing placebo with 1 mg/d rasagiline as add-on therapy to 100 mg riluzole in amyotrophic lateral sclerosis (ALS) in 250 enrolled patients. For entry, the El Escorial Criteria for the diagnosis of ALS will be used. The patients have to be stable on riluzole at least 4 weeks prior to randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria
- •Disease duration more than 6 months and less than 3 years (inclusive). Disease onset defined as date of first muscle weakness, excluding fasciculations and cramps
- •Vital capacity more than 50% of normal (slow vital capacity; best of three measurements)
- •Age: ≥ 18 years
- •Continuously treated with 100 mg riluzole for at least four weeks
- •Capable of thoroughly understanding all information given and giving full informed consent according to GCP
- •Women of childbearing age must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate i.e. less than 1% per year) when used consistently and correct are such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), or double-barrier methods (condom or diaphragm with spermicidal agent or IUD), sexual abstinence or vasectomized partner
排除标准
- •Previous participation in another clinical study within the preceding 12 weeks
- •Tracheostomy or assisted ventilation of any type during the preceding three months
- •Gastrostomy
- •Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS
- •Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
- •Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine.
- •Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphene.
- •Patients on serotonin reuptake inhibitors (SSRIs). This includes fluoxetine or fluvoxamine.
- •Patients on dextromethorphan, St. John's wort, cyclobenzaprine or other MAO inhibitors (selective or non-selective)
- •Patients taking Antidepressants
- •Confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT greater than 3 times the upper limit of the normal range)
- •Renal insufficiency (serum creatinine more than 2.26 mg/dL)
- •Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms
- •Known hypersensitivity to any component of the study drug
- •Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency
- •Female with childbearing potential, if no adequate contraceptive measures are used
- •Pregnancy or breast-feeding females
研究组 & 干预措施
Rasagiline
Experimental
Rasagiline
1 mg/day; 18 months
干预措施: Rasagiline (Drug)
Placebo
Placebo Comparator
once daily, 18 months
干预措施: Placebo (Drug)
结局指标
主要结局
Survival in ALS-Patients with Rasagiline compared to placebo
时间窗: 18 Months
次要结局
- Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)(18 Months)
- Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life(18 Months)
- Change of slow vital capacity(18 Months)
研究者
Albert Christian Ludolph, Prof.
MD, Prof.
University of Ulm
研究点 (15)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)HIV-1 InfectionNCT03859739Merck Sharp & Dohme LLC21
已完成
不适用
A Study on the Effectiveness Evaluation in Stroke Patients Using Lower Limb Assistive Walking DevicesStrokeNCT06564480Second Affiliated Hospital, School of Medicine, Zhejiang University100
已完成
1 期
Study of JS001 in Participants With Advanced Solid TumorsSolid TumorsNCT02857166Shanghai Junshi Bioscience Co., Ltd.24
已完成
1 期
A First in Human Study of RT001 in Patients With Friedreich's AtaxiaFriedreich's AtaxiaNCT02445794Retrotope, Inc.19
撤回
1 期
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)HIV-1Human Immunodeficiency Virus 1Immunodeficiency Virus Type 1, HumanHuman Immunodeficiency Virus Type 1NCT05700734Merck Sharp & Dohme LLC